background: systemic lupus erythematosus is a kind of multi-system autoimmune disorder with unknown aetiology and it produces antibodies against various tissues. case presentation:the patient wasa 44-year-old woman with a history of systemic lupus erythematosus for approximately five years, along with underlying diseases including peptic ulcers, asthma, hypertension and diabetes in the past 10 ...

MicroRNAs (miRNAs) are endogenous, non-coding, single-stranded RNAs about 21 nucleotides in length. miRNAs have been shown to regulate gene expression and thus influence a wide range of physiological and pathological processes. Moreover, they are detected in a variety of sources, including tissues, serum, and other body fluids, such as saliva. The role of miRNAs is evident in various malignant ...

Pleural involvement in systemic diseases is usually a sign of lesions occurring at other levels. Despite the low incidence (around 1%) of pleural effusions caused by systemic diseases, more often connective tissue diseases, such as rheumatoid arthritis or systemic lupus erythematosus, may present with this. Similarly, vasculitis, such as Wegener's granulomatosis, Churg-Strauss syndrome, or less...

Gonadal function is significantly affected in many acute and chronic systemic diseases. As the function of the testes and the ovaries is determined by the integrity of the hypothalamic-pituitary-gonadal axis, it is obvious that a systemic disease may affect one or more levels of the axis in such a manner that the gonadal dysfunction may have various clinical and laboratory manifestations. In th...

Although much emphasis has been placed on the primary presentations of breast cancer, little focus has been placed on how systemic illnesses may affect the breast. In this article, we discuss systemic illnesses that can manifest in the breast. We summarize the clinical features, imaging, histopathology, and treatment recommendations for endocrine, vascular, systemic inflammatory, infectious, an...

In an ideal scenario, a biomarker would both reveal the driver of disease and identify an effective treatment. In oncology, genetic biomarkers that molecularly or clinically classify patient populations for targeted therapies, e.g., BRAF [1] and HER-2 [2], have been clinically validated and are reaching this ideal. However, biomarkers are necessarily based on the pathobiology of the underlying ...